Regulus Publishes Data Showing miR-33 Antagonism Impacts Atherosclerosis

Mice treated with a miR-33 antagonist displayed increased HDL-C, enhanced reverse cholesterol transport to the plasma, liver, and feces, and reductions in plaque size and lipid content.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.